News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The Q1 2025 also witnessed a successful launch of Allegra D
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
ekincare has raised a total funding of $22M since 2015 till date
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Subscribe To Our Newsletter & Stay Updated
